ASPIC

send to a friend share this

A aneuploidia identifica subgrupos de doentes com evolução clínica desfavorável no cancro da mama de grau 1 e grau 2

Neste estudo, que incluiu 684 doentes com carcinoma invasivo da mama e “fcancro da mama, António Evaristo Pintoollow-up” de longo prazo, observámos que aquelas que apresentaram tumores aneuploides com grau 1 e grau 2 de diferenciação, quando comparados com os diplóides, tiveram pior prognóstico, tanto na série total como no cancro precoce da mama (estádios I/IIA da doença). Este achado tem implicações terapêuticas, pois estas doentes são potenciais candidatas a terapia adjuvante adaptada ao risco.

 

Autores e Afiliações:

The future of the postdoc: is the system broken?

An article published in Nature covers the future of postdocs and explains the failures and potential solutions of the broken postdoctoral system.

 

Read more here: http://www.eacr.org/news/news_detail.php?id=160

The future of the postdoc: is the system broken?

An article published in Nature covers the future of postdocs and explains the failures and potential solutions of the broken postdoctoral system.

 

Read more here: http://www.eacr.org/news/news_detail.php?id=160

Cancer Vaccines 2015

Cancer Vaccines 2015

Oncology Meets Immunology

Hotel Crowne Plaza, Athens, Greece

 

12- 13 June, 2015

 

See more informations here: http://www.eacr.org/user_uploads/files/meetings/SAVE%20THE%20DATE%20IMMUNOLOGY%208.pdf

Oncology Meets Immunology

Hotel Crowne Plaza, Athens, Greece

 

12- 13 June, 2015

 

See more informations here: http://www.eacr.org/user_uploads/files/meetings/SAVE%20THE%20DATE%20IMMUNOLOGY%208.pdf

First Symposium on Immunomodulation in Cancer & Regeneration

Atmosfera m, Rua Júlio Dinis, nº 158/160, 5th floor, Porto, Portugal 

 

02 July, 2015


See more informations here: http://www.sicr2015.ineb.up.pt/
 

First Symposium on Immunomodulation in Cancer & Regeneration

Atmosfera m, Rua Júlio Dinis, nº 158/160, 5th floor, Porto, Portugal 

 

02 July, 2015


See more informations here: http://www.sicr2015.ineb.up.pt/
 

Single dose radiotherapy: information misleading patient’s trust on cancer research

Recently, the Portuguese press announced in several front pages that a private Foundation (Fundação Champalimaud) was capable to cure 90% of cancer patients with single dose radiotherapy. This announcement was very unfortunate. It is obviously a false statement from the professionals and scientists standpoint, but not for patients. Patients and their families tend to invest their expectations in whatever promise, even if the “good news” may sound as suspicious to everybody that is not sufficiently acquainted with science progress (and limitations).